A Phase II, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab IMAB362 in Combination with Nab-Paclitaxel and Gemcitabine Nab-P + GEM as First Line Treatment in Subjects with Claudin 18.2 CLDN18.2 Positive, Metastatic Pancreatic Adenocarcinoma

Brief Summary

Type:
Pancreatic

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03816163

Study #:
STUDY00144118

Start Date:
Dec 02, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03816163

View Complete Trial Details & Eligibility at ClinicalTrials.gov